BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25385688)

  • 1. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 2. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
    Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC
    J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.
    Thomas NE; Edmiston SN; Kanetsky PA; Busam KJ; Kricker A; Armstrong BK; Cust AE; Anton-Culver H; Gruber SB; Luo L; Orlow I; Reiner AS; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Parrish EA; Hao H; Gibbs DC; Frank JS; Ollila DW; Begg CB; Berwick M; Conway K;
    J Invest Dermatol; 2017 Dec; 137(12):2588-2598. PubMed ID: 28842324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF and MC1R in melanoma: different in head and neck tumors?
    Fink EC; Fisher DE
    J Invest Dermatol; 2013 Apr; 133(4):878-80. PubMed ID: 23486431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
    Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
    J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
    [No Abstract]   [Full Text] [Related]  

  • 6. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
    Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
    J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis.
    Zanna I; Caini S; Raimondi S; Saieva C; Masala G; Massi D; Cocorocchio E; Queirolo P; Stanganelli I; Gandini S
    Mol Carcinog; 2021 Mar; 60(3):167-171. PubMed ID: 33444485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
    Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
    Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
    [No Abstract]   [Full Text] [Related]  

  • 12. Germline MC1R variants and BRAF mutant melanoma.
    Hacker E; Hayward NK
    J Invest Dermatol; 2008 Oct; 128(10):2354-6. PubMed ID: 18787543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
    Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
    [No Abstract]   [Full Text] [Related]  

  • 15. Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells.
    Herraiz C; Journé F; Ghanem G; Jiménez-Cervantes C; García-Borrón JC
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2244-52. PubMed ID: 23000456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MC1R germline variants confer risk for BRAF-mutant melanoma.
    Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
    Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interplay between secreted ligands and receptors in melanoma.
    Herraiz C; Jiménez-Cervantes C; Sánchez-Laorden B; García-Borrón JC
    Semin Cell Dev Biol; 2018 Jun; 78():73-84. PubMed ID: 28676423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
    Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.
    Hacker E; Hayward NK; Dumenil T; James MR; Whiteman DC
    J Invest Dermatol; 2010 Jan; 130(1):241-8. PubMed ID: 19571821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.